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Abstract: Hemorrhagic hereditary telangiectasia (HHT) type 2 patients have increased activation of
the phosphatidylinositol 3-kinase (PI3K) signaling pathway in telangiectasia. The main objective
is to evaluate the activation of the PI3K pathway in cutaneous telangiectasia of HHT1 patients. A
cutaneous biopsy of a digital hand telangiectasia was performed in seven HHT1 and eight HHT2
patients and compared with six controls. The study was approved by the Clinical Research Ethics
Committee of our center. A histopathological pattern with more dilated and superficial vessels that
pushed up the epidermis was identified in HHT patients regardless of the type of mutation and was
associated with older age, as opposed to the common telangiectasia pattern. The mean proliferation
index (Ki-67) was statistically higher in endothelial cells (EC) from HHT1 than in controls. The
percentage of positive EC for pNDRG1, pAKT, and pS6 in HHT1 patients versus controls resulted in
higher values, statistically significant for pNDRG1 and pS6. In conclusion, we detected an increase in
EC proliferation linked to overactivation of the PI3K pathway in cutaneous telangiectasia biopsies
from HHT1 patients. Our results suggest that PI3K inhibitors could be used as novel therapeutic
agents for HHT.
Keywords: hemorrhagic hereditary telangiectasia; rare diseases; telangiectasia; transforming growth
factor-beta (TGF-β); Smad pathway; phosphatidylinositol 3-kinase; mTOR inhibitors
1. Introduction
Hereditary hemorrhagic telangiectasia (HHT) or Rendu–Osler–Weber syndrome (ORPHA774) is
a vascular autosomal-dominant germline disease, with an incidence of 1:6000 [1,2]. HHT is caused by
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mutations in genes involved in the transforming growth factor-beta (TGF-β) superfamily [3]. Mutations
in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are detected in approximately
85% of cases submitted to molecular diagnosis for clinical suspicion of HHT, and cause HHT1 and
HHT2, respectively [2,3]. Both proteins are specifically expressed in endothelial cells (ECs). Endoglin
is an auxiliary co-receptor that promotes BMP9 signaling through the activin receptor-like kinase 1
(ALK1). Both proteins contribute to the signaling hub formed by BMP9–Endoglin–ALK1–Smad with
high impact in EC proliferation, migration, and survival during angiogenesis [4]. The loss of function
of endoglin and ALK1 proteins provokes an anomalous vascular overgrowth [4,5].
Although endoglin and ALK1 are components of the same BMP9 receptor complex, they are
structurally and functionally different proteins and mutations in their genes are related with different
clinical phenotypes [3,4]. Pulmonary and cerebral arteriovenous malformations (AVMs) are more
common in patients with HHT1 and vascular hepatic malformations in those with HHT2 [6–8]. In spite
of these differences in large vessels, telangiectasia is the characteristic lesion in the microvasculature in
both HHT1 and HHT2 patients. Histopathologically, telangiectasia shows dilated post capillary venules
directly connected with dilated arterioles losing the capillary bed [9]. These dilated microvessels are
more prone to hemorrhage due to fragile walls and turbulent blood flow, especially those located in
mucosae, such as nasal or gastrointestinal (GI) ones. Telangiectasia in nasal mucosae are the cause of
spontaneous recurrent epistaxis, the earliest and most common clinical manifestation of HHT [6–8].
Limited data exist about the histological pattern of human cutaneous telangiectasia and possible
differences between HHT1 and HHT2 patients [9].
Therapeutic strategies aim at reducing potential complications caused by vascular malformations,
but there is currently no curative treatment for HHT [10,11]. Using heterozygous ALK1 mouse retinas
and cultured ECs, we found that loss of ALK1 leads to increased EC proliferation as a result of the
overactivation of PI3K (phosphatidylinositol 3-kinase) signaling. In the same study, mutations in
ALK1 result in increased activation of PI3K signaling in human telangiectasia of patients with HHT2
compared with control vessels; furthermore, vascular retinal hyperplasia in a heterozygous ALK1
mouse model was rescued by pharmacological inhibition of PI3K activity [12]. Actually, the PI3K
signaling pathway is involved in EC proliferation, migration, and survival by activating downstream
of various angiogenic growth factors [13,14]. Taken together, these findings suggest a therapeutic
intervention with PI3K pathway inhibitors, such as mTOR (mammalian target of rapamycin) inhibitors,
for the treatment of HHT [12,14].
The goal of this work was to demonstrate the hyperactivation of the PI3K pathway in vascular
lesions of patients with HHT1 compared with control vessels. Secondary objectives were to analyze
endothelial proliferation in HHT1 patients compared to controls and to assess different histological
patterns between HHT1 and HHT2 patients.
2. Materials and Methods
2.1. Study Design and Patients
Patients were selected from the referral HHT Unit at the Hospital Universitari de Bellvitge
(Barcelona, Spain). This HHT unit serves adult patients from all over Catalonia (Spain), which has
about seven million inhabitants. The inclusion criteria were having a definite diagnosis according to
the Curaçao Criteria, mandatory cutaneous telangiectasia on the fingertip, and a positive genetic study
for ENG mutations [15,16]. Seven HHT1 patients were included. Control samples were obtained from
healthy skin in resection borders from melanomas. HHT2 patients were those used in our previous
study on PI3K signaling pathway activation [12] and two new HHT2 patients. All selected patients
gave their signed informed consent for telangiectasia biopsy in accordance with local ethics committee
requirements. The study was approved by the Clinical Research Ethics Committee of the Hospital
Universitari de Bellvitge (Barcelona, Spain; ethic approval number PR098/16).
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2.2. Clinical Variables
Clinical characteristics at baseline and complementary tests were collected. Using the Curaçao
criteria (recurrent epistaxis, cutaneous/mucosal telangiectasia, visceral involvement, and a first line
family member with HHT), a diagnosis of HHT is considered “definite” if three or more criteria are
present [16]. The severity of nosebleeds was measured according to the epistaxis severity score (ESS).
Epistaxis is considered moderate or severe if ESS results are >4 or >7 points, respectively [17]. For the
screening of pulmonary AVMs, a contrast transthoracic echocardiography (TTE) was performed [8,15].
The Barzilai scale was used to establish the degree of right–left shunt and the need for a thoracic
computed tomography (CT) angiography to confirm the presence of pulmonary AVM [18]. In addition,
an abdominal CT angiography was performed to study hepatic and/or abdominal AVMs. Hepatic
involvement was defined according to the three classical patterns of abnormal vascular communications:
Portovenous (from portal vein to hepatic vein), arteriovenous (from hepatic artery to hepatic vein),
and arterioportal (from hepatic artery to portal vein) [8,19]. A GI endoscopic digestive study was
performed according to guidelines, when there was disproportionate anemia to the degree of epistaxis
or objectively confirmed overt GI bleeding [15]. Genetic tests were performed by the company Health
in Code, S.L. (A Coruña, Spain) using next-generation sequencing [20].
2.3. Cutaneous Telangiectasia Biopsy
A punch biopsy (3 mm) from a cutaneous telangiectasia on the fingertip was obtained by a senior
dermatologist under the usual conditions of sterility and hygiene. Samples were encrypted according
to a code assigned to each patient. Biopsies were fixed in a formol buffer, dehydrated, and embedded
in paraffin.
2.4. Histopathological Evaluation
Tissue sections (3 µm) were stained with hematoxylin and eosin for morphological analysis. To
assess possible different histological patterns between HHT1 and HHT2 patients, we restained the
samples from the six HHT2 human telangiectasia biopsies performed for our previous study on PI3K
signaling pathway activation [12], plus two new HHT2 patients we were able to add to the series.
Histological evaluation was performed by a senior pathologist.
2.5. Immunohistochemistry Studies
Tissue sections (3 µm) were stained by immunohistochemistry to determine the amount of
expression of various proteins. Samples were deparaffinized in xylene and rehydrated in downgraded
alcohols and distilled water. Antigen retrieval was performed under high-pressure conditions for 3 or
4 min in citrate buffer, pH 6 or 6.5, and incubated with 3% H2O2 for 10 min. Samples were then blocked
with 1:20 goat serum for 1 h followed by incubation overnight at 4 ◦C with corresponding antibody.
In an attempt to describe the vessel area and to study the extracellular matrix, we performed
immunohistochemistry with mouse monoclonal antibody anti-CD34 (Cat. #M7165; Dako, Carpenteria,
CA, USA), an EC marker, and for mouse monoclonal antibody anti-Collagen IV (#M785; Dako),
an extracellular component secreted by ECs. We also performed immunohistochemistry for monoclonal
rabbit antibody anti–Ki-67 (SP6, Cat. MA5-15420; Thermo Fisher Scientific, Waltham, MA, USA),
a proliferation marker, and for antiphospho-NDRG1 (Thr 346, Cat. #5482; Cell Signaling Technology,
Inc., Beverly, MA, USA), polyclonal rabbit antiphospho-AKT antibody (Ser 473, Cat. #4060; Cell
Signaling Technology, Inc.), and polyclonal rabbit antibody antiphospho-S6 (Ser 240/244, Cat. #2215;
Cell Signaling Technology, Inc.), all markers of PI3K pathway activation. Sections were incubated with
the specific secondary antibody, EnVision (Dako), followed by the DAB developing system (Dako).
CD34 and pAKT were amplified with tyramide biotinXX reaction (Invitrogen #B40931, Thermo Fisher
Scientific) and streptavidine–horseradish peroxidase (HRP) before DAB developing. Samples were
counterstained with hematoxylin and visualized under light microscopy.
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Three microscope images (200×) from each biopsy were used for vessels area analysis and collagen
IV quantifications. Image J Software (developed at the National Institutes of Health and the Laboratory
for Optical and Computational Instrumentation, University of Wisconsin, Madison, WI, USA) was
used to measure the area of all CD34 immunostained vessels. Collagen IV was quantified on the higher
amount zones for each vessel.
As a quality control and to confirm previous results of PI3K signaling pathway activation in
HHT2 patients, we attempted to repeat all these immunohistochemistry studies in three HHT2 patients
used in our previous study plus two new additional HHT2 samples [12]. For all samples, negative
controls were performed, in which the section followed exactly the same protocol but in the absence of
primary antibody.
2.6. Statistical Analysis
A descriptive statistical analysis was performed for all categorical and continuous variables
expressed as proportions or means with standard deviations (SD), respectively. The statistical
significance of group differences in continuous variables was determined using two-tailed
Mann–Whitney U tests (p < 0.05) because no normal conditions were observed. The statistical
significance of group differences in categorical variables was determined using two-tailed Fischer exact
test (p < 0.05). Correlation was analyzed using two-tailed Pearson correlation (p < 0.01). Analyses
were performed using SPSS, version 18 for the PC (SPSS, Inc., Chicago, IL, USA), and graphs were
designed using GraphPad Prism (v5.0b, GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Histopathological Vascular Pattern in Human Cutaneous Telangiectasia Biopsies
We analyzed cutaneous telangiectasia biopsies from seven patients with HHT1 with mutations in
the ENG gene and from eight HHT2 patients with mutations in the ACVRL1 gene. In HHT1 group, the
mean age was 50.8 ± 10.2 years and four out of seven patients were female, while in HHT2 group, the
mean age was 54.1 ± 9.2 years and four out of eight patients were female. All patients had a family
history of HHT, and a definite diagnosis was made according to the Curaçao criteria. In our cohort,
several types of variants were observed in the ENG gene: two nonsense, one frameshift (detected in
three patients who were relatives), and one missense, as well as one large deletion involving exons
1–3 (copy number variant, CNV). In the ACVRL1 gene, four pathogenic missense variants (one of
them shared by three patients, including two relatives), one frameshift, and one in-frame deletion
were identified.
In 71% of the HHT1 patients (five out of seven patients) pulmonary AVMs were identified and
embolized, whereas in 87.5% of the HHT2 patients (seven out of eight patients) liver involvement was
detected. Nosebleed severity measured by ESS was moderate (>4 points) in 57% of HHT1 patients and
in 62.5% of HHT2 patients. The clinical characteristics of these patients are shown in Table 1.
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Table 1. Hereditary hemorrhagic telangiectasia type 1 and 2 patient characteristics.
No. Age,Years M/F TTE Thoracic CT Abdominal CT GI Telangiectasia CI, L/min/m
2 ESS Mutations
1 66 F 2 Pulmonary AVM RUL, LUL, LLL(embolized) Pancreatic telangiectasias Esophagus–duodenum 3.06 4.75
ENG: Exon 6: p.(Tyr258*) (c.774C > A)
NONSENSE
2 * 52 F 1 Pulmonary AVM LLL (embolized) No pathological findings Gastroduodenal,proximal–middle jejunum 2.47 3.04
ENG: Exon 7: p.(Val323Leufs*10)
(c.967_968delGT)
FRAMESHIFT
3 59 F 2 Pulmonary AVM LUL, RLL, RUL(embolized) Ileal-jejunum AVM
Stomach–proximal–middle
jejunum 2.32 7.68
ENG: Exon 3: p.(Arg93*) (c.277C > T)
NONSENSE
4 38 M 3 Pulmonary AVM LLL, RUL (embolized) Intrahepatic telangiectasiasHepatic AP shunt Not performed 3.4 3.84
ENG: Exon 9: p.(Cys412Tyr) (c.1235G > A)
MISSENSE
5 * 43 M 3 Pulmonary AVM LUL, RUL (embolized) No pathological findings Not performed 2.44 4.42
ENG: Exon 7: p.(Val323Leufs*10)
(c.967_968delGT)
FRAMESHIFT
6 42 M 1 No pathological findings Intrahepatic telangiectasias Stomach–ascending colon 2.77 3.33 ENG: Exon 1–3: (c.-3659_361-537del)CNV (COPY NUMBER VARIANT)
7 * 56 F 2 No pathological findings No pathological findings Gastroduodenal–Ileocecalvalve 3.36 5.47
ENG: Exon 7: p (Val323Leufs*10)
(c.967_968delGT)
FRAMESHIFT
8 + 62 F 1 No pathological findings
Intrahepatic telangiectasias
Hepatic AV shunt Hepatic artery
enlargement FNH Intrapancreatic
AVM Ileal AVM Cecal AVM
Uterine AVM
Not performed 3.74 2.83
ACVRL1: Exon 3: p.(Thr82del)
(c.244_246delACC)
IN-FRAME DELETION
9 49 M 1 No pathological findings No pathological findings Not performed 2.28 6.38 ACVRL1: Exon 3: p.(Cys77Arg) (c.229T > C)MISSENSE
10 ** 41 F 3 Pulmonary AVM LLL
Intrahepatic telangiectasias
Hepatic AV shunt Hepatic artery
enlargement NRH Uterine AVM
Not performed 3.12 2.93 ACVRL1: Exon 10: p.(Arg479Pro) (c.1436G > C)MISSENSE
11 **,+ 70 F 0 No pathological findings
Hepatomegaly Hepatic AV shunt
Hepatic artery enlargement
Intrapancreatic AVM Left renal
artery aneurysm
Not performed 3.7 6.59 ACVRL1: Exon 10: p.(Arg479Pro) (c.1436G > C)MISSENSE
12 49 M 0 Not performed
Intrahepatic telangiectasias
Intrapancreatic AVM
Gastro-omental artery aneurysms
Not performed 4.57 13.5 ACVRL1: Exon 10: p.(Arg479Pro) (c.1436G > C)MISSENSE
13 + 51 M 1 No pathological findings Hepatomegaly Hepatic AP shuntHepatic artery enlargement Not performed 3.3 6.05
ACVRL1: Exon 10: p.(Arg484Trp) (c.1450C > T)
MISSENSE
14 51 F 1 No pathological findings Hepatic telangiectasias HepaticAP shunt Hepatic AV shunt Not performed 3.2 1.41
ACVRL1: Exon 3: p.(Pro23Leufs*2) (c.68delC)
FRAMESHIFT
15 60 M 0 No pathological findings
Hepatic telangiectasias Hepatic
AP shunt Hepatic AV shunt
Intrapancreatic AVM
Gastroduodenal 2.9 6.09 ACVRL1: Exon 3: p.(Arg67Gln) (c.200G > A)MISSENSE
Contrast transthoracic echocardiography (TTE). Computed tomography (CT). Arteriovenous malformation (AVM). Cardiac index (CI). Epistaxis severity score (ESS). Female (F). Right
upper lobe (RUL), left upper lobe (LUL), left lower lobe (LLL), right lower lobe (RLL). AP indicates arterioportal (hepatic artery to portal vein); AV, arteriovenous (hepatic artery to hepatic
vein); Focal nodular hyperplasia (FNH); Nodular regenerative hyperplasia (NRH); * Patients 2, 5, and 7 are relatives. ** Patient 11 is the mother of patient 10. + HHT2 patients already
enrolled in our previous study with available sample to repeat PI3K immunohistochemistry studies [12].
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These telangiectasia biopsies were assessed by a senior pathologist and there were no different
histological patterns between HHT1 and HHT2. However, some differences were identified in
the telangiectasia biopsies regardless of the type of mutation. One group resembled conventional
telangiectasia characterized by the presence of dilated microvessels at the superficial dermis, while
the others showed even more dilated vessels expanding the papillary dermis between rete ridges and
pushing up the epidermis resembling an angiokeratoma-like pattern (Figure 1). We analyzed whether
there were differences between these two histological subgroups and clinical data. We observed that
patients with superficial dilated vessels were older (57.2 vs. 47.2 years; p = 0.042) and had higher
nosebleed severity measured by ESS (5.4 vs. 4; p = 0.049) compared to patients with a conventional
histological pattern (Table 2).
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Figure 1. Hematoxylin and eosin (HE) microsco e i ages. Scale bars, 100 µm. (A) Examples of
conventional telangiectasia characterized by the presence of dilated microvessels at the superficial
dermis (black arrows). Normal vessels are indicated with red arrows. One HHT1 patient and one
HHT2. (B) Examples of more dilatated vessels expanding the papillary dermis between rete ridges that
crowd up the epidermis layer (black arrows) (angiokeratoma-like pattern). One HHT1 patient and
one HHT2.
Table 2. Clinical characteristics of HHT patients according to different histological patterns.
Conventional Pattern
n (%) or Mean (SD)
Angiokeratoma-Like Pattern
n (%) or Mean (SD) P
Patients 7 (46.6) 8 (53.3) NA
Female gender 3 (42.8) 5 (62.5) 0.619
Age, years 47.2 (9.5) 57.2 (7.0) 0.042 *
Mutation
ENG 5 (87.5) 2 (25) 0.132
ACVRL1 2 (28.5) 6 (75)
ESS 3.9 (0.6) 5.4 (1.5) 0.049 *
Standard deviation (S ); ); activin (ACVRL1); epistaxis everity score (ESS); * p < 0. 5.
3.2. Vascular Size and Endothelial Cell Proliferation Are Increased in Cutaneous Telangiectasia Biopsies of
Patients with HHT1 and HHT2 Compared to Controls
We analyzed cutaneous telangiectasia biopsies from seven patients with HHT1 and from six
controls. The control group had a mean age of 60 ± 21.8 (range, 32–83) years and four (66.7%) were
male. Unfortunately, in three of the six HHT2 patients used in our previous study, no sample was
available to repeat immunohistochemistry studies.
Patients with HHT1 and HHT2 were separately compared with controls. Both HHT1 and HHT2
showed significantly more enlarged vessels than controls when we measured the area of CD34-positive
vessels. The basement membrane (BM) of these enlarged vessels was studied through collagen IV
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and we observed a higher presence of this marker in both HHT patients than in controls, though only
statistically significant for HHT1 (Figure 2).
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Figure 2. Increased vessels size and collagen IV staining in T1 and T2 cutaneous telangiectasia
biopsies. ( ) e atoxylin and eosin ( E), C 34, and collagen IV staining of one control, two HHT1
patients and one HHT2 patient biopsies. Scale bars, 100 µm. (B) Quantification of the vessel area in
controls (n = 6), 1 ( 7), and HHT2 patients (n = 5). Results are represented as % relative to
the control. Error bars indicate the standard error of the mean. Statistical significance of two-tailed
Mann–Whitney U tests: ** p < 0.01. (C) Quantification of the collagen IV width in controls (n = 6),
HHT1 (n = 7), and HHT2 patients (n = 5). Results are represented as % relative to the control. Error
bars indicate the standard error of the mean. Statistical significance of two-tailed Mann–Whitney U
tests: ** p < 0.01.
EC proliferation was analyzed by immunohistochemistry for Ki-67. The mean proliferation index
was higher in ECs from HHT1 and HHT2 telangiectasia than in controls, statistically significant for
both (Figure 3).
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Figure 3. Increased endothelial cell proliferation in HHT1 cutaneous telangiectasia biopsies. (A) Ki-67
(brown nuclei, arrows) staining of endothelial cells in one control and two HHT1 patients. Scale bars,
100 µm. (B) Quantification of the percentage of Ki-67-positive endothelial cells in controls (n = 6),
HHT1 patients (n = 7), a d HHT2 patients (n = 5). Error bars indicate the standard erro s of the mean.
Statistical significance of two-tailed Mann–Whitney U ests: ** p < 0.01.
3.3. Overstimulation of the PI3K Pathway in Cutaneous ela tasia Biopsies of Patients with HHT1
Compared to Control Vessels
To analyze PI3K pathway activation, we perfor i unohistochemistry for phosphorylated
proteins pNDRG1, pAKT, and pS6. The mean percentage of ECs positive for these markers resulted in
higher values in HHT1 patients than in controls, being statistically significant for pNDRG1 (p = 0.001)
and pS6 (p = 0.022). In accordance with previous results, HHT2 patients also showed statistically
significant higher percentage of positive ECs than controls for pNDRG1 (p = 0.004) and pS6 (p = 0.004)
(Figure 4).
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patients (n = 7), and HHT2 patients (n = 4). Results are represented as % relative to the control. Error
bars indicate the standard error of the mean. (C) Quantification of the percentage of pNDRG1-positive
endothelial cells in controls (n = 6), HHT1 patients (n = 7), and HHT2 patients (n = 5). Results are
represented as % relative to the control. Error bars indicate the standard error of the mean. Statistical
significance of two-tailed Mann–Whitney U tests: ** p < 0.01. (D) Quantification of the percentage of
pS6-positive endothelial cells in controls (n = 6), HHT1 patients (n = 7), and HHT2 patients (n = 5).
Results are represented as % relative to the control. Error bars indicate the standard error of the mean.
Statistical significance of two-tailed Mann–Whitney U tests: * p < 0.05; ** p < 0.01.
We also compared the activation of PI3K pathway between HHT1 and HHT2 samples and no
statistical differences were found. Moreover, we analyzed whether there were differences between
those two histological subgroups mentioned above and PI3K pathway activation and we did not find
significant differences.
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4. Discussion
Notwithstanding that they are caused by mutations in different genes, both HHT1 and HHT2
share telangiectasia as the characteristic lesion in the microvasculature [5]. In fact, we have not found
different histological patterns between HHT1 and HHT2 in human telangiectasia biopsies. The two
patterns described were significantly correlated with age. Patients with more dilated vessels in contact
with the epidermis (angiokeratoma-like pattern) were older and had a higher ESS than patients with
typical smaller telangiectasia at the superficial dermis. Actually, age influences the natural history of
HHT, as clinical manifestations in HHT are age-dependent [7,8,21]. Epistaxis usually worsened with
age and GI bleeding usually began at the fifth or sixth decades of life [15,22]. These age-dependent
bleeding manifestations could be explained by changes in telangiectasia, although other factors could
also influence them. The fact that telangiectasia become larger and more superficial with age, even
pushing up the epidermis as we observed, could make telangiectasia more prone to hemorrhage.
Larger vascular malformations in the liver or the lungs also appear in adulthood, reflecting the active,
lifelong angiogenesis process [8,15,21].
In our study, we have found an enlargement in vessels and a higher collagen IV expression in both
HHT1 and HHT2 human telangiectasia biopsies than in controls. BMs are composed of macromolecules
such as collagen IV [23]. In recent years, the understanding of the BM has changed from a mere
structural component of tissues, to be considered an active modulator of blood vessel formation. Type
IV collagen promotes cell adhesion, migration, differentiation, and growth, playing a critical role in EC
proliferation and angiogenesis [23–26]. Moreover, in cutaneous collagenous vasculopathy, a benign rare
acquired idiopathic microangiopathy characterized by diffuse telangiectasia, immunohistochemical
staining revealed extensive deposition of type IV collagen around the blood vessels [27,28]. The exact
role of type IV collagen in telangiectasia development in HHT, needs further investigation.
In the present study, we detected an increase in EC proliferation linked to an increase of the
PI3K pathway activation compared to controls in cutaneous human telangiectasia biopsies from
patients with HHT1. Similar results have been obtained in endoglin-null endothelial cells [29] and
in endoglin-deficient animal models [5]. Endoglin and ALK1 are key components of the endothelial
BMP9–Endoglin–ALK1–Smad hub signaling pathway that, in collaboration with the Notch signaling
pathway, induces the maturation phase of the angiogenic process [4,5,30,31]. In this phase, ECs
stop migration and proliferation, enter quiescence, produce extracellular matrix, and attract mural
cells [12,30,31]. A decrease in the BMP9–Endoglin–ALK1–Smad axis, given by heterozygous mutations
in ENG or ACVRL1 genes, both converge in an increase in the PI3K pathway (and their readouts pAKT,
pS6, and pNDGR1) that, in consequence, increases proliferation [4,5,13,30]. PI3K pathway inhibition
improved vascular malformations in mouse models of HHT [14]. In addition, PI3K overstimulation
has been shown to play a key role in other vascular malformations that also generate AVMs [32].
All these findings, together with similar results in our previous study with HHT2 patients, suggest
that pharmacological block of the PI3K axis could be a therapeutic option for HHT disease [12,14].
mTOR inhibitors, such as sirolimus or everolimus, block the PI3K signaling pathway [33]. These
drugs have shown efficacy in a phase II study for the treatment of patients affected by vascular
malformations [34]. Concerning telangiectasia, sirolimus treatment also caused the regression of
cutaneous and internal telangiectasias in a HHT patient, while treatment with the novel orally-available
PI3K inhibitor BKM120 (also named buparlisib) caused a decrease in epistaxis in a HHT2 patient with
ovarian cancer [35,36]. mTOR inhibitors have been thoroughly tested as immunosuppressant agents
and are specially recommended in patients with liver transplantation for hepatocellular carcinoma [37].
However, optimal doses and the long-term benefit/risk ratio of these drugs for the treatment of HHT
patients are unknown. Because loss-of-function mutations in ALK1 also cause vascular overgrowth,
some authors aimed at activating this pathway as a therapeutic value. In a recent study, tacrolimus
(FK-506) activated Smad1/5/8 and opposed to the pro-angiogenic gene expression associated with ALK1
loss-of-function in human umbilical vein ECs (HUVECs) and prevented the hypervascularization in a
BMP9/10-immunodepleted retina mouse model [38]. Further investigation is needed to determine
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whether concomitant use of both mTOR–PI3K inhibitors and ALK1 activators provides additional
benefit in the treatment of HHT patients.
5. Conclusions
In conclusion, besides the conventional histological telangiectasia appearance we have identified
an angiokeratoma-like pattern that could be related to age. Human HHT1 and HHT2 telangiectasia
biopsies showed higher collagen IV deposition than controls. Immunohistochemical staining revealed
an increase in endothelial cell proliferation linked to an increased activation of the PI3K pathway
in HHT1. Our results suggest that PI3K inhibitors (or mTOR inhibitors) could be used as novel
therapeutic agents for both HHT1 and HHT2 patients.
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